Literature DB >> 29090466

Age of platelet concentrates and time to the next transfusion.

Camila Caram-Deelder1,2, Johanna G van der Bom1,2, Hein Putter3, Anja Leyte4, Daan van de Kerkhof5, Dorothea Evers1,6, Erik A Beckers7, Floor Weerkamp8, Francisca Hudig9, Jaap Jan Zwaginga1,6, Jan M M Rondeel10, Karen M K de Vooght11, Nathalie C V Péquériaux12, Otto Visser13, Jonathan P Wallis14, Rutger A Middelburg1,2.   

Abstract

BACKGROUND: Storage time of platelet (PLT) concentrates has been negatively associated with clinical efficacy outcomes. The aim of this study was to quantify the association between storage time of PLT concentrates and interval to the next PLT transfusion for different types of PLT components, stored for up to 7 days and transfused to transfusion-dependent hematooncology patients with thrombocytopenia. STUDY DESIGN AND METHODS: From a cohort of patients from 10 major Dutch hospitals, patients were selected whose transfusion patterns were compatible with PLT transfusion dependency due to hematooncologic disease. Mean time to the next transfusion and mean differences in time to the next transfusion for different storage time categories (i.e., fresh, <4 days; intermediate, 4-5 days; and old, >5 days) were estimated, per component type, using multilevel mixed-effects linear models.
RESULTS: Among a cohort of 29,761 patients who received 140,896 PLT transfusions we selected 4441 hematooncology patients who had received 12,724 PLT transfusions during periods of PLT transfusion dependency. Transfusion of fresh, compared to old, buffy coat-derived PLTs in plasma was associated with a delay to the next transfusion of 6.2 hours (95% confidence interval [CI], 4.5-8.0 hr). For buffy coat-derived PLTs in PAS-B and -C this difference was 7.7 hours (95% CI, 2.2-13.3 hr) and 3.9 hours (95% CI, -2.1 to 9.9 hr) while for apheresis PLTs in plasma it was only 1.8 hours (95% CI, -3.5 to 7.1 hr).
CONCLUSION: Our results indicate that the time to the next transfusion shortens with increasing age of transfused buffy coat-derived PLT concentrates. This association was not observed for apheresis PLTs.
© 2017 AABB.

Entities:  

Mesh:

Year:  2017        PMID: 29090466     DOI: 10.1111/trf.14388

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

Review 2.  Platelet Additive Solutions: A Review of the Latest Developments and Their Clinical Implications.

Authors:  Pieter F van der Meer; Dirk de Korte
Journal:  Transfus Med Hemother       Date:  2018-03-09       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.